Organon (OGN) stock price, chart and financials
Price chart
Financials
- Revenue (quarter)
- $1.6B
- Gross margin
- 52.68%
- Net income (quarter)
- $108.0M
- Net margin
- 3.41%
- Return on equity
- 24.04%
- Book value per share
- $3.83
- Price to book
- 3.59
- Debt to assets
- 92.37%
- Payout ratio
- 46.94%
- Dividend yield
- 0.58%
Company profile
Organon & Cois a globalised healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day. Its operations include the following product portfolios: Women's Health: Itbwomen's health portfolio of products is sold by prescription mainly in two therapeutic areas: contraception, with key brands such as Nexplanon, and fertility, with key brands such as Follistim. other women's health products include the Jada, which is intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted. The General Medicines portfolio includes biosimilars and established brands. Companies' current biosimilars portfolio spans across immunology and oncology-related treatments.
Frequently asked questions
Is Organon (OGN) profitable?
Yes. Organon earned $209.0M in net income over the trailing twelve months, a net margin of 3.41%.
How much revenue does Organon (OGN) make?
Organon generated $6.1B in revenue over the trailing twelve months, down 2.26% year over year.
What is OGN's P/E ratio?
Organon trades at 17.3 times trailing twelve-month earnings, on an EPS of $0.79.
How do I buy stock in Organon (OGN)?
OGN trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.
Quotes and charts are not real-time and must not be relied on for trade decisions or valuation.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.